Pevion, Protagen and Alethia all raise new venture funds; Australian biotech plots IPO

 @FierceBiotech: Roche plots layoffs as it focuses on R&D. Story | Follow @FierceBiotech

 @JohnCFierce: Ooh. Celldex shares (a) plunge (b) swoon (c) dive or (d) in a meltdown ? | Follow @JohnCFierce

> Switzerland's Pevion Biotech AG raised CHF10 million from its existing investors--BZ Bank, BB Biotech Ventures and Core Capita--and named Evert Kueppers as its new chief executive officer, succeeding Thomas Stauffer. Pevion release

> Germany's Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced a second round of finance totaling €10 million. Protagen release

> Canada's Alethia Biotherapeutics has rounded up $9.6 million in Series A money and plans to use the funds to push its lead therapy into clinical development. Alethia release

> Australia's Broadvector says that it plans to use the money from its $8.5 million float to fund development of a new prostate cancer therapy. Story

> Duke University spin-off Humacyte, which is working on artificial blood vessels, raised $12 million in a debt offering. Story

And Finally... Scientists say that the brains of the lowly cockroach, one of the globe's most tenacious survivors, are loaded with chemicals that can kill MRSA and other nasty bugs. And they want to enlist the insect in the fight to develop a new generation of more effective antibiotics. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.